Short Interest in Immunic, Inc. (NASDAQ:IMUX) Decreases By 32.0%

Immunic, Inc. (NASDAQ:IMUX) was the recipient of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 2,550,000 shares, a drop of 32.0% from the January 31st total of 3,750,000 shares. Based on an average trading volume of 933,800 shares, the days-to-cover ratio is currently 2.7 days.

Immunic Trading Up 0.9 %

Shares of NASDAQ IMUX opened at $1.17 on Wednesday. The stock has a market cap of $105.39 million, a price-to-earnings ratio of -0.95 and a beta of 1.87. Immunic has a 1-year low of $0.92 and a 1-year high of $2.11. The stock’s 50-day moving average is $1.04 and its 200 day moving average is $1.25.

Hedge Funds Weigh In On Immunic

Large investors have recently modified their holdings of the company. Invesco Ltd. purchased a new position in shares of Immunic during the 4th quarter valued at about $37,000. Virtu Financial LLC purchased a new position in Immunic in the 3rd quarter worth approximately $50,000. HB Wealth Management LLC purchased a new position in Immunic in the 4th quarter worth approximately $81,000. Barclays PLC purchased a new position in Immunic in the 4th quarter worth approximately $84,000. Finally, Jane Street Group LLC increased its stake in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. 51.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research report on Saturday, February 22nd. Finally, D. Boral Capital reiterated a “buy” rating and set a $17.00 price target on shares of Immunic in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.